1. Goyal A, Mansel RE, Efamast study Group. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J. 2005;11(1):41-47.
2. Roberts MM, Elton RA, Robinson SE, French K. Consultations for breast disease in general practice and hospital referral patterns. Br J Surg. 1987;74(11):1020-1022.
3. Fentiman IS. Tamoxifen and mastalgia. An emerging indication. Drugs. 1986;32(6):477-480.
4. Fentiman IS, Caleffi M, Hamed H, Chaudary MA. Dosage and duration of tamoxifen for mastalgia. A controlled trial. Br J Surg. 1988;75(9):845-846.
5. Preece PE, Richards AR, Owen GM, Hughes LE. Mastalgia and total body water. Br Med J. 1975;4(5995):498-500.
6. Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P. Benign breast disease. 1: Hormonal investigation. Obstet Gynecol. 1979;53(4):457-460.
7. Swain MC, Hayward JL, Bulbrool RD. Plasma oestradiol and progesterone in benign breast disease. Eur J Cancer. 1973;9(8):553-556.
8. England PC, Skinner LG, Cottrell KM, Sellwood RA. Serum oestradiol-17 beta in women with benign and malignant breast disease. Br J Cancer. 1974;30(6):571-576.
9. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Twenty four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res. 1977;37(12):4655-4659.
10. Cole EN, Sellwood RA, England PC, Griffiths K. Serum prolactin concentration on benign breast disease throughout the menstrual cycle. Eur J Cancer. 1977;13(6):597-603.
11. Peters F, Pickardt CR, Zimmerman G, Breckwoldt M. PRL, TSH and thyroid hormones in benign breast disease. Klin Wochenschr. 1981;59(8):403-407.
12. Kumar S, Mansel RE, Hughes LE, et al. Prolactin response tothyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer. 1984;53(6):1311-1315.
13. Khanna AK, Tapodar JK, Khanna HD, Khanna S, Khanna A. Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders. Eur J Surg. 2002;168(11):631-634.
14. Horrobin DF, Manku MS. Premenstrual syndrome and premenstrual breast pain: disorders of essential fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids. 1989;37(4):255-261.
15. Gateley CA, Maddox PR, Pritchard GA, et al. Plasma fatty acid profiles in benign breast disorders. Br J Surg. 19902;79(5):407-409.
16. Sharma AK, Mishra SK, Salia M, Ramesh V, Bal S. Cyclical mastalgia--is it a manifestation of aberration in lipid metabolism? Indian J Physiol Pharmacol. 1994;38(4):267-271.
17. Peters F, Diemer P, Mecks O, Behnken L LJ. Severity of mastalgia in relation to milk duct dilatation. Obstet Gynecol. 2003;101(1):54-60.
18. Downey,HM, Deadman JM, Davis C, Leinster SJ. Psychologic characteristics of women with cyclical mastalgia. Breast Dis. 1993;6:99-105.
19. Ramirez AJ, Jarrett SR, Hamed H, Smith P, Fentiman IS. Psychosocial adjustment of women with mastalgia. The Breast. 1995;4(1):48-51.
20. Barros AC, Mottola J, Ruiz CA, Borges MN, Pinotti JA. Reassurance in the treatment of mastalgia. Breast J. 1999;5(3):62-65.
21. Wilson MC, Sellwood RA. Therapeutic value of a supporting brassiere in mastodynia. Br Med J. 1976;2(6027):90.
22. Hadi MS. Sports brassiere: is it a solution for mastalgia? Breast J. 2000;6(6):407-409.
23. Boyd NF, McGuire V, Shannon P, et al. Effect of a low-fat high-carbohydrate diet on symptoms of cyclical mastopathy. Lancet. 1988;332(8603):128-132.
24. Ernster VL, Mason L, Goodson WH, et al. Effects of caffeine free diet on benign breast disease: a randomised trial. Surgery. 1982;91:263-267.
25. Minton JP, Foeking MK, Webster DJ, Matthews RH. Response of fibrocystic disease to caffeine withdrawal and correlation with cyclic nucleotides with breast disease. Am J Obstet Gynecol. 1979;135(1):157-158.
26. Colak T, Ipek T, Kanik A, Ogetman Z, Aydin S. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196(4):525-530.
27. London RS, Sundaram GS, Murphy L, Manimekalai S, Reynolds M, Goldstein PJ. The effect of vitamin E on mammary dysplasia: a double-blind study. Obstet Gynecol. 1985;65(1):104-106.
28. Ernster VL, Goodson WH, Hunt TK, Petrakis NL, Sickles EA, Miike R. Vitamin E and benign breast "disease": a double-blind, randomized clinical trial. Surgery. 1985;97(4):490-494.
29. Meyer EC, Sommers DK, Reitz CJ, Mentis H. Vitamin E and benign breast disease. Surgery. 1990;107(5):549-551.
30. Pashby NL, Mansel RE, Hughes LE. A clinical trial of evening primrose oil inmastalgia. Br J Surg. 1981;68:801.
31. Pye JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet. 1985;2(8451):373-377.
32. Greenblatt RB, Dmowske WP, Mhesh VB, Scholer HF. Clinical studies with an antigonadotrophin-Danazol. Fertil Steril. 1971;22(2):102-112.
33. Asch RH, Greenblatt RB. The use of an impeded androgen Danazol in the management of benign breast disorders. Am J Obstet Gynecol. 1977;127(2):130-134
34. Hinton CP, Bishop HM, Holliday HW, Doyle PJ, Blamey RW. A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain. Br J Clin Pract. 1986;40(8):326-330.
35. Millet AV, Dirbas FM. Clinical management of breast pain: a review. Obstet Gynecol Surv. 2002;57(7):451-461.
36. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol. 1999;180(1 pt 1):18-23.
37. Nazli K, Syed S, Mahmood MR, Ansari F. Controlled trial of the prolactin inhibitorbromocriptine (Parlodel) in the treatment of severe cyclical mastalgia. Br J ClinPract. 1989;43(9):322-327.
38. Mansel RE, Dogliotti L. European multicentre trial of bromocriptine in cyclical mastalgia. Lancet. 1990;335(8683):190-193.
39. Fentiman IS, Caleffi M, Brame K, Hayward JL. Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet.1986;327(8476):287-288.
40. Fentiman IS, Caleffi M, Hamed H, Chaudary MA. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. Br J Surg. 1988;75(9):845-846.
41. Messinis IE, Lolis D. Treatment of premenstrual mastalgia with tamoxifen. Acta Obstet Gynecol Scand. 1988;67(4):307-309.
42. Mansal E, Goyal A, Preece P, et al. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol. 2004;191(6):1942-1949.
43. Daverey A, Saxena R, Tewari S, Goel SK, Dwivedi A. Expression of estrogen receptor co-regulators SRC-1, RIP140 and NCoR and their interaction with estrogen receptor in rat uterus, under the influence of ormeloxifene. J Steroid Biochem Mol Biol. 2009;116(1-2):93-101.
44. Kamboj VP, Ray S, Dhawan BN. Centchroman. Drugs Today. 1992;28:227-232.
45. Kamboj VP, Kar AB, Ray S, Grover PK, Anand N. Antifertility activity of 3,4-trans-2,2-dimethyl-3-phenyl-4- p(pyrrolidine ethoxy)-phenyl-7 methoxy chromen. Indian J Exp Biol. 1971;9(1):103-104.
46. Kamboj VP, Sing MM, Kar AB. Effect of some nonsteroidal antifertility agents on the biochemistry of the uterus and uterine fluids in rats. Indian J Exp Biol. 1973;11(6):479-483.
47. Kamboj VP, Setty BS, Chandra H, Roy SK, Kar AB. Biological profile of centchroman--A new post-coital contraceptive. Indian J Exp Biol. 1977;15(12):1144-1150.
48. Datta JK, Roy S. Effect of centchroman on morphological and biochemical changes induced by testosterone propionate in uterus of rats. Indian J Exp Biol. 1979;17(10):1061-1063.
49. Dhar A, Srivastava A. Role of centchroman in regression of Mastalgia and Fibroadenoma. World J Surg. 2007;31(6):1178-1184.
50. Jain Bhupendra Kumar, Bansal Amit, Choudhary Deepti, Garg Pankaj Kumar, Mohanty Debajyoti. Centchroman vs tamoxifen for regression of mastalgia: A randomized controlled trial. Int J Surg. 2015;15:11-16.
51. Prakash Lakhmichand Tejwani, Anurag Srivastava, Hrishikesh Nerkar, et al. Centchroman Regresses Mastalgia: A Randomized Comparison with Danazol. Indian J Surg. 2011;73(3):199-205.